RIVAROXABAN AS THE MAIN COMPONENT OF THE TREATMENT OF PATIENTS WITH OBLITERATING ATHEROSCLEROSIS OF THE LOWER EXTREMITIES | Zendy

AI Assistant Blog Pricing

Open Access

RIVAROXABAN AS THE MAIN COMPONENT OF THE TREATMENT OF PATIENTS WITH OBLITERATING ATHEROSCLEROSIS OF THE LOWER EXTREMITIES

Author(s) -

I. V. Tverdovsky

Publication year - 2019

Publication title -

clinical anesthesiology and intensive care

Language(s) - English

Resource type - Journals

eISSN - 2616-5945

pISSN - 2411-9164

DOI - 10.31379/2411.2616.13.1.10

Subject(s) - rivaroxaban , medicine , component (thermodynamics) , cardiology , warfarin , atrial fibrillation , physics , thermodynamics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.